Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of FCN-159 in NF2-associated nerve sheath tumors
ChiCTR2400086826Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of luvometinib in nerve sheath neoplasm, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Objective response rate. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
luvometinib
03
Conditions
nerve sheath neoplasm
Beyond the preview
Go deeper on ChiCTR2400086826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086826.